More than 1,200 patients with T2DM complicated with obesity were randomly divided into 1mg SMG group, 2.4mg SMG group, or placebo group and given once a week in STEP2 research
12 weeks on, 4 weeks off) or as part of a long-term protocol depending on your goals and your doctors assessment
G.OrtinskiP
Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, et al
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial